Topics

Benign Prostatic Hyperplasia Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08042019] Prices from USD $1799

00:58 EST 9 Nov 2019 | BioPortfolio Reports

Summary

Benign Prostatic Hyperplasia pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Benign Prostatic Hyperplasia RD activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.


Extensive Coverage of Pipeline Candidates

The Benign Prostatic Hyperplasia report covers all the preclinical compounds and clinical compounds under evaluation for treatment of Benign Prostatic Hyperplasia as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.


Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Benign Prostatic Hyperplasia with details of current status of development, pipeline phase, drug target, mechanism of action MoA, route of administration RoA, participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.


Companies participating in Benign Prostatic Hyperplasia pipeline Profiled in detail

Key players actively participating in Benign Prostatic Hyperplasia pipeline are profiled along with their RD progress in Benign Prostatic Hyperplasia treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.


Information Sourced from inhouse Proprietary Databases

The report is developed using information from inhouse database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.



Report assists users in taking actionable steps

Benign Prostatic Hyperplasia pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Benign Prostatic Hyperplasia treatment pipeline.



The report includes:


The research work provides comprehensive overview of Benign Prostatic Hyperplasia pipeline and treatment landscape

Complete list of drug candidates from discovery to preregistration phases are analyzed

Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio

Detailed drug profiles of Benign Prostatic Hyperplasia pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed

Research and Development progress and trial details, results wherever available, are also included in the Benign Prostatic Hyperplasia pipeline study

All recent news and developments related to Benign Prostatic Hyperplasia drugs are provided

Original Article: Benign Prostatic Hyperplasia Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08042019] Prices from USD $1799

NEXT ARTICLE

More From BioPortfolio on "Benign Prostatic Hyperplasia Pipeline Drugs and Companies, Q2 2019 [Report Updated: 08042019] Prices from USD $1799"

Quick Search

Relevant Topics

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...